The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD Pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Ji Hyun Kim
No Relationships to Disclose
 
Boram Park
No Relationships to Disclose
 
Jung-Yun Lee
No Relationships to Disclose
 
Suk-Joon Chang
No Relationships to Disclose
 
Yoo-Young Lee
No Relationships to Disclose
 
Chel Hun Choi
No Relationships to Disclose
 
Jeong-Yeol Park
No Relationships to Disclose
 
Dae-Yeon Kim
No Relationships to Disclose
 
Dae Gy Hong
No Relationships to Disclose
 
Hyun-Woong Cho
No Relationships to Disclose
 
Jae-Yun Song
No Relationships to Disclose
 
Yun Hwan Kim
No Relationships to Disclose
 
Ki Hyung Kim
No Relationships to Disclose
 
Sang-Yoon Park
No Relationships to Disclose
 
Seob Jeon
No Relationships to Disclose